Myelin-reactive Cluster of differentiation 4-positive effector memory T-cell (Myelin-reactive CD4+ Tem)

Myelin-reactive Cluster of differentiation 4-positive (CD4+) effector memory T-cells are a specialized subset of the immune system that mistakenly identify myelin proteins—specifically Myelin Basic Protein (MBP), Myelin Oligodendrocyte Glycoprotein (MOG), and Proteolipid Protein (PLP)—as foreign antigens (Sospedra & Martin, 2005, PMID: 15771581). In healthy individuals, these cells are typically kept in check by regulatory mechanisms, but in patients with Multiple Sclerosis (MS), they become activated and cross the blood-brain barrier to initiate an inflammatory cascade within the central nervous system (Kaskow & Baecher-Allan, 2018, PMID: 29610319). Once inside, they secrete pro-inflammatory cytokines like IFN-gamma and IL-17, which recruit other immune cells and lead to the destruction of the myelin sheath and underlying axons (PubMed: 30116015). These cells are characterized by the expression of memory markers such as CD45RO and specific T-cell receptors (TCRs) that recognize myelin epitopes presented by MHC class II molecules (UniProt). Therapeutic strategies targeting these cells range from broad immunosuppression and sequestration to more sophisticated antigen-specific approaches designed to induce immune tolerance (Arnon & Aharoni, 2004, PMID: 15326298). For instance, Glatiramer acetate acts as an altered peptide ligand to shift the immune response, while Natalizumab prevents these cells from adhering to and crossing the vascular endothelium (Polman et al., 2006, PMID: 16510744). Emerging therapies like ATX-MS-1467 aim to induce tolerance specifically in these autoreactive populations without affecting the rest of the immune system (PubMed: 31142635). By specifically modulating or depleting these autoreactive T-cells, clinicians aim to halt disease progression and preserve neurological function in neurodegenerative autoimmune conditions.

Other names

Myelin-specific CD4+ T-cellAutoreactive myelin T-cellMBP-specific T-cellMOG-specific T-cellPLP-specific T-cell

Therapeutic strategies involve the depletion of autoreactive T-cells, sequestration within lymph nodes to prevent CNS entry, or the induction of antigen-specific immune tolerance to suppress the inflammatory response against myelin proteins (PubMed: 15326298, PMID: 16510744).